RQM+, the global leader in medtech services, announces the acquisition of CRO Kottmann, a leading contract research organization (CRO) renowned for its unparalleled customer service, clinical research and its commitment to quality in the key German market. This major transaction confirms RQM+’s desire to ensure its strategic growth and strengthen its presence in Europe. This also underlines its dominant position in the growing medtech sector.
The integration of CRO Kottmann strengthens RQM+’s international presence and its ability to offer a complete end-to-end service to its customers, from the preclinical phase to the commercialization of products. This new acquisition also reinforces RQM+’s rapid growth as a leading medtech CRO, driving innovation for its existing and new customers in important markets.
“We are very excited about this major acquisition. Thanks to the synergy between RQM+ and CRO Kottmann, we will reach new heights in the industry. The German market, which is proving to be a very important geographic area for RQM+, is well known for its focus on science, innovation and business intelligence,” says David Novotny, COO Testing Services at RQM+. “With the combined expertise of both companies, we will achieve faster and more efficient operational results that will facilitate market entry for our customers. »
Renowned for its unparalleled customer service and commitment to quality, CRO Kottmann brings a wealth of industry-leading knowledge and expertise that will enable RQM+ to strengthen its international presence, particularly in Europe.
“We have always had the same approach to customer service and quality advice. These aligned core values, along with our shared ambition to drive the growth of science and innovation, will make this partnership a success in clinical research. We look forward to being able to offer our customers an even more comprehensive range of clinical research services. Going forward, our customers can continue to use our services to conduct global studies across the globe,” says Tanja Kottmann, MD, CEO of CRO Kottmann.
As RQM+ continues its growth trajectory, the acquisition of CRO Kottmann underscores its commitment to providing unparalleled service to medical technology manufacturers of all sizes. Acquisition Secures a Powerful Blend of Clinical Affairs and Regulatory Experience, Industry-Leading Capabilities, and Unmatched Geographical Reach, Paving the Way for Rapid and Innovative Medtech Solutions .
DLA Piper acted as legal advisor and Translink Corporate Finance acted as M&A advisor for RQM+.
Source link: https://www.businesswire.com/
